Citadel Advisors
CNTX icon

Citadel Advisors’s Context Therapeutics CNTX Stock Holding History

Citadel Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$367K Buy
140,017
+105,637
+307% +$247K ﹤0.01% 10012
2025
Q4 		$50.5K Sell
34,380
-68,983
-67% -$80.6K ﹤0.01% 12030
2025
Q3 		$100K Buy
+103,363
New +$83.8K ﹤0.01% 11851
2025
Q1 		– Sell
-29,900
Closed -$31.4K – 14602
2024
Q4 		$31.4K Buy
+29,900
New +$51.7K ﹤0.01% 12830
2024
Q2 		– Sell
-15,041
Closed -$20.8K – 14376
2024
Q1 		$20.8K Sell
15,041
-839
-5% -$944 ﹤0.01% 12994
2023
Q4 		$17.9K Buy
15,880
+5,442
+52% +$5.85K ﹤0.01% 12715
2023
Q3 		$15.8K Buy
+10,438
New +$11.8K ﹤0.01% 12809
2022
Q2 		– Sell
-18,516
Closed -$40K – 12996
2022
Q1 		$40K Buy
+18,516
New +$38.9K ﹤0.01% 12928

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors's CNTX Position: Q1 2026 in Review

Citadel Advisors increased its Context Therapeutics (CNTX) stake by 307% in Q1 2026, buying an estimated $247K and bringing the position to 140,017 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #10012.

Citadel Advisors first reported a position in CNTX in Q1 2022 and has held it in 8 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Citadel Advisors held 140,017 shares of Context Therapeutics worth $367K as of Q1 2026.
  • Citadel Advisors bought 105,637 Context Therapeutics shares in Q1 2026, an estimated $247K.
  • Context Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10012 holding.
  • Citadel Advisors first reported a position in Context Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.